KONECT RESILIA Aortic Valved Conduit (AVC) Real-world Study Assessing Safety and Performance (KONECTION)
KONECTION is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in up to 250 participants who will receive the KONECT RESILIA aortic valved conduit, Model 11060A.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Subjects in the KONECTION study will be enrolled at up to 20 sites in Europe and Canada. The population will be participants requiring replacement of their diseased native or prosthetic aortic valve, and the associated repair or replacement of a damaged or diseased ascending aorta.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Sabrina Hundt, PhD
- Numero di telefono: +49 (0)151 67550601
- Email: Sabrina_Hundt@edwards.com
Luoghi di studio
-
-
-
Berlin, Germania, 13353
- Reclutamento
- Deutsches Herzzentrum der Charité
-
Investigatore principale:
- Herko Grubitzsch, PD Dr. med.
-
-
Bavaria
-
München, Bavaria, Germania, 80636
- Reclutamento
- TUM Klinikum Deutsches Herzzentrum
-
Investigatore principale:
- Markus Krane, Prof. Dr. med.
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Germania, 53127
- Reclutamento
- Universitätsklinikum Bonn
-
Investigatore principale:
- Farhad Bakhtiary, Prof. Dr. med.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The target population includes adult candidates who require replacement of their native or prosthetic aortic valve, and the associated repair or replacement of a damaged or diseased ascending aorta.
Descrizione
Inclusion Criteria:
- 18 years or older at the time of informed consent
- Have a diseased native or prosthetic aortic valve and a damaged or diseased ascending aorta that requires aortic valved conduit replacement surgery with the KONECT RESILIA AVC
- Provide written informed consent
- Willing to follow protocol requirements
Exclusion Criteria:
- Active endocarditis or endocarditis within 3 months prior to the study index procedure
- Emergency procedure
- Stage 4 renal disease (estimated glomerular filtration rate [eGFR] <30 excluded) or requiring dialysis
- Less than 2-year life expectancy due to non-cardiovascular life-threatening disease in the opinion of the study investigator
- High predicted risk of mortality prior to the procedure: Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) ≥8%
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Edwards KONECT RESILIA AVC
Subjects who were treated with the Edwards KONECT RESILIA AVC |
Surgical replacement of the aortic valve and ascending aorta with the Edwards KONECT RESILIA AVC |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of participant's freedom from death and/or device related reintervention
Lasso di tempo: ≤ 30 days
|
Participants' freedom from valve-related death or valve- and/or graft-related reintervention. Time to events were estimated by Kaplan-Meier method. |
≤ 30 days
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Participant's linearized rate of thromboembolism
Lasso di tempo: Events occurring ≥ 31 days and up through 5 years post-implant
|
A linearized rate percentage is calculated by the following equation: [(Total number of late adverse events in each category/total number of late patient years) x 100]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact. |
Events occurring ≥ 31 days and up through 5 years post-implant
|
|
Participant's linearized rate of valve thrombosis
Lasso di tempo: Events occurring ≥ 31 days and up through 5 years post-implant
|
A linearized rate percentage is calculated by the following equation: [(Total number of late adverse events in each category/total number of late patient years) x 100]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact. |
Events occurring ≥ 31 days and up through 5 years post-implant
|
|
Participant's linearized rate of major paravalvular leak
Lasso di tempo: Events occurring ≥ 31 days and up through 5 years post-implant
|
A linearized rate percentage is calculated by the following equation: [(Total number of late adverse events in each category/total number of late patient years) x 100]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact. |
Events occurring ≥ 31 days and up through 5 years post-implant
|
|
Participant's linearized rate of endocarditis
Lasso di tempo: Events occurring ≥ 31 days and up through 5 years post-implant
|
A linearized rate percentage is calculated by the following equation: [(Total number of late adverse events in each category/total number of late patient years) x 100]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact. |
Events occurring ≥ 31 days and up through 5 years post-implant
|
|
Participant's linearized rate of major hemorrhage
Lasso di tempo: Events occurring ≥ 31 days and up through 5 years post-implant
|
A linearized rate percentage is calculated by the following equation: [(Total number of late adverse events in each category/total number of late patient years) x 100]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact. |
Events occurring ≥ 31 days and up through 5 years post-implant
|
|
Percentage of participant's with freedom from death and/or device related reintervention
Lasso di tempo: 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10- Years follow-up
|
Participants' freedom from valve-related death or valve- and/or graft-related reintervention. Time to events were estimated by Kaplan-Meier method. |
1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10- Years follow-up
|
|
Participant's functional improvement over time from baseline for New York Heart Association (NYHA) Class
Lasso di tempo: Baseline, 1 month, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10- Years follow-up
|
The New York Heart Association functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. Patients with cardiac disease but without resulting limitation of physical activity. Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present even at rest. |
Baseline, 1 month, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10- Years follow-up
|
|
Participant's average mean gradient measurement over time
Lasso di tempo: 1 month, 1-, 3-, and 5- Years follow-up
|
Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve. |
1 month, 1-, 3-, and 5- Years follow-up
|
|
Participant's average peak gradient measurement over time
Lasso di tempo: 1 month, 1-, 3-, and 5- Years follow-up
|
Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve. |
1 month, 1-, 3-, and 5- Years follow-up
|
|
Participant's average Effective Orifice Area (EOA) measurement over time
Lasso di tempo: 1 month, 1-, 3-, and 5- Years follow-up
|
Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size and type of valve. |
1 month, 1-, 3-, and 5- Years follow-up
|
|
Participant's average Effective Orifice Area Index (EOAI) measurement over time
Lasso di tempo: 1 month, 1-, 3-, and 5- Years follow-up
|
Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size of the patient and the size and type of valve. |
1 month, 1-, 3-, and 5- Years follow-up
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Markus Krane, Prof. Dr. med., TUM Universitätsklinikum Deutsches Herzzentrum
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2025-02
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data will not be available to other researchers.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .